
MINDACT

Trial Highlights

The Microarray In Node-negative (or 1-3 positive lymph node) Disease may Avoid ChemoTherapy (MINDACT) clinical trial is a study to help breast cancer patients and their physicians optimize chemotherapy treatment decisions using MammaPrint®

Here is a look at some of the impressive data from this POSITIVE trial:

112 Institutions









of patients spared from unnecessary chemotherapy



results



MammaPrint is a 70-gene test that will assess your cancer's risk of recurrence within 5-years. Patients diagnosed with stage I or II invasive breast cancer that is lymph node negative or lymph node positive (up to 3 nodes) and ≤ 5cm, are eligible for Agendia Breast Cancer testing.

Breast Cancer recurrence assay comparison:

Number of genes evaluated			
Number of reference (or control) genes			
FDA 510(k) cleared			
Definitive Low Risk or High Risk Results?			
(No intermediate / indeterminate results)			
Results don't reassess traditional			
breast cancer markers ER, PR, HER2 or Ki-67?			
Results independent of 5 years of hormonal therapy or therapy compliance? (tamoxifen or AI)			

 70	16
 465	5
 ✓	×
 ✓	×
 ✓	×
 ✓	×

MammaPrint® Oncotype DX®

MammaPrint data is based off of MINDACT publication results and information from www.agendia.com Oncotype DX data is based off of TAILORx study results and information from www.oncotypedx.com



